JP2008520591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520591A5 JP2008520591A5 JP2007541607A JP2007541607A JP2008520591A5 JP 2008520591 A5 JP2008520591 A5 JP 2008520591A5 JP 2007541607 A JP2007541607 A JP 2007541607A JP 2007541607 A JP2007541607 A JP 2007541607A JP 2008520591 A5 JP2008520591 A5 JP 2008520591A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- clusterin
- oligonucleotide
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52294804P | 2004-11-23 | 2004-11-23 | |
| US60/522,948 | 2004-11-23 | ||
| US52296004P | 2004-11-24 | 2004-11-24 | |
| US60/522,960 | 2004-11-24 | ||
| PCT/CA2005/001775 WO2006056054A1 (en) | 2004-11-23 | 2005-11-22 | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008520591A JP2008520591A (ja) | 2008-06-19 |
| JP2008520591A5 true JP2008520591A5 (https=) | 2008-11-27 |
| JP4980919B2 JP4980919B2 (ja) | 2012-07-18 |
Family
ID=36497699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007541607A Expired - Fee Related JP4980919B2 (ja) | 2004-11-23 | 2005-11-22 | Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080014198A1 (https=) |
| EP (1) | EP1814595B1 (https=) |
| JP (1) | JP4980919B2 (https=) |
| AU (1) | AU2005309274B2 (https=) |
| CA (1) | CA2584646C (https=) |
| DK (1) | DK1814595T3 (https=) |
| ES (1) | ES2456017T3 (https=) |
| PL (1) | PL1814595T3 (https=) |
| PT (1) | PT1814595E (https=) |
| SI (1) | SI1814595T1 (https=) |
| WO (1) | WO2006056054A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4785252B2 (ja) | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| CA2584646C (en) * | 2004-11-23 | 2015-11-03 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
| EA034462B1 (ru) | 2009-11-24 | 2020-02-11 | Алетиа Байотерапьютикс Инк. | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований |
| SG192957A1 (en) | 2011-03-15 | 2013-09-30 | Univ British Columbia | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| US9822170B2 (en) | 2012-02-22 | 2017-11-21 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
| MD20140101A2 (ro) * | 2013-02-22 | 2015-02-28 | Alethia Biotherapeutics Inc. | Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5417978A (en) * | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| ATE234919T1 (de) * | 1993-12-23 | 2003-04-15 | Biognostik Ges | Antisense nukleinsäuren zur vorbeugung und behandlung von beschwerden in welchen die exprimierung von c-erbb-2 eine rolle spielt |
| AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| NZ331217A (en) * | 1996-02-14 | 2000-02-28 | Novartis Ag | Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand |
| US5910583A (en) * | 1996-11-04 | 1999-06-08 | Duke University | Antisense oligonucleotides against ERBB-2 |
| US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| JP4785252B2 (ja) * | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| WO2002097114A2 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
| WO2003062421A1 (en) * | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| US7019017B2 (en) * | 2002-05-14 | 2006-03-28 | Baylor College Of Medicine | Small molecule inhibitors of HER2 expression |
| SI1530636T1 (sl) * | 2002-08-21 | 2010-12-31 | Stry Liaison Ofiice The University Of British Columbia Umiversity Indu | Zdravljenje melanoma z zniĹľanjem nivojev klusterina |
| KR101238701B1 (ko) * | 2002-08-21 | 2013-03-05 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| US20040224914A1 (en) * | 2003-04-18 | 2004-11-11 | The University Of British Columbia | Method for treatment of angiogenic disorders |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| CA2584646C (en) * | 2004-11-23 | 2015-11-03 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
-
2005
- 2005-11-22 CA CA2584646A patent/CA2584646C/en not_active Expired - Fee Related
- 2005-11-22 ES ES05810600.6T patent/ES2456017T3/es not_active Expired - Lifetime
- 2005-11-22 DK DK05810600.6T patent/DK1814595T3/da active
- 2005-11-22 JP JP2007541607A patent/JP4980919B2/ja not_active Expired - Fee Related
- 2005-11-22 PT PT58106006T patent/PT1814595E/pt unknown
- 2005-11-22 SI SI200531838T patent/SI1814595T1/sl unknown
- 2005-11-22 EP EP05810600.6A patent/EP1814595B1/en not_active Expired - Lifetime
- 2005-11-22 PL PL05810600T patent/PL1814595T3/pl unknown
- 2005-11-22 US US11/718,815 patent/US20080014198A1/en not_active Abandoned
- 2005-11-22 AU AU2005309274A patent/AU2005309274B2/en not_active Ceased
- 2005-11-22 WO PCT/CA2005/001775 patent/WO2006056054A1/en not_active Ceased
-
2010
- 2010-09-20 US US12/886,027 patent/US20110142827A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102443358B1 (ko) | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 | |
| JP6814788B2 (ja) | Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法 | |
| ES2709495T3 (es) | Modulación de la expresión del transductor de señales y activador de la transcripción 3 (stat3) | |
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| JP2018525030A5 (https=) | ||
| EA015570B1 (ru) | Фармацевтическая композиция | |
| EP3207135A2 (en) | Isotopologues of smad7 antisense oligonucleotides | |
| EA029137B1 (ru) | Модулирование экспрессии вируса гепатита в (hbv) | |
| JP6158833B2 (ja) | ベータ−カテニン関連疾患を処置するための有機組成物 | |
| EA009670B1 (ru) | МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E | |
| CN104755621A (zh) | 癌症治疗 | |
| CN113544271B (zh) | Malat1表达的调节剂 | |
| JP2005530486A5 (https=) | ||
| JP2006502243A5 (https=) | ||
| JP7275164B2 (ja) | Ｅｚｈ２発現の調節因子 | |
| JP2008520591A5 (https=) | ||
| JP6722586B2 (ja) | アンチセンス抗悪性腫瘍剤 | |
| TW201016222A (en) | RNA antagonists targeting GLI2 | |
| CN113795581A (zh) | 具有缩短的有义链的双链核酸抑制剂分子 | |
| JP4980919B2 (ja) | Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療 | |
| KR20150086442A (ko) | ANT2 siRNA를 함유하는 HER2 표적 항암제에 대한 내성 극복을 위한 조성물 | |
| Wang et al. | Antisense imaging of epidermal growth factor-induced p21WAF-1/CIP-1 gene expression in MDA-MB-468 human breast cancer xenografts | |
| JP7216381B2 (ja) | Ｒｎａ作用抑制剤及びその利用 | |
| TW201102073A (en) | RNA antagonists targeting GLI2 for the treatment of leukemia | |
| HK40077247A (en) | Antisense oligonucleotide sequences for silencing the human l1-met transcript in tumours |